Nov 21 (Reuters) - Mayne Pharma Group Ltd MYX.AX:
EXPECTS GROWTH IN UNDERLYING EBITDA AND FREE CASH FLOW IN FY25
FOR JULY-OCT UNDERLYING EBITDA OF A$14.7M
JUL-OCT REVENUE A$132.5 MILLION
Further company coverage: MYX.AX
((Reuters.Briefs@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.